Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Macrophage-Derived Chemokine (MDC/CCL22) ELISA kit

Human Macrophage-Derived Chemokine (MDC/CCL22) ELISA kit

  • 中文名称：
    人巨噬细胞来源的趋化因子(MDC/CCL22)酶联免疫试剂盒
  • 货号：
    CSB-E04660h
  • 规格：
    96T/48T
  • 价格：
    ￥3200/￥2500
  • 其他：

产品详情

  • 产品描述：
         CCL22，也称为小细胞肺癌分泌蛋白-1（MDC），是C-C趋化因子家族中的一种趋化因子。它主要由树突状细胞和肿瘤细胞等产生，并且能够吸引CCR4受体表达的细胞，如调节性T细胞和Th2细胞等。CCL22在多种疾病中发挥着重要作用，如过敏性疾病、自身免疫性疾病、肿瘤等。
         j9九游会登录入口首页生物所提供的Human Macrophage-Derived Chemokine (MDC/CCL22) ELISA kit属于ELISA检测试剂盒，采用双抗夹心法定量检测人血清、血浆、细胞培养上清、组织匀浆样本中的CCL22，其灵敏度为10.324 pg/mL，检测范围为15.625 pg/mL-1000 pg/mL。
     
  • 别名：
    A 152E5.1 ELISA Kit; ABCD 1 ELISA Kit; ABCD1 ELISA Kit; C C motif chemokine 22 ELISA Kit; CC chemokine STCP 1 ELISA Kit; CC chemokine STCP-1 ELISA Kit; ccl 22 ELISA Kit; Ccl22 ELISA Kit; CCL22_HUMAN ELISA Kit; Chemokine (C C motif) ligand 22 ELISA Kit; DC/B CK ELISA Kit; DCBCK ELISA Kit; Macrophage-derived chemokine ELISA Kit; MDC ELISA Kit; MDC(1-69) ELISA Kit; MDC(7-69) ELISA Kit; MGC34554 ELISA Kit; SCYA22 ELISA Kit; Small inducible cytokine subfamily A (Cys Cys) member 22 ELISA Kit; Small inducible cytokine subfamily A; member 22 ELISA Kit; Small-inducible cytokine A22 ELISA Kit; STCP 1 ELISA Kit; STCP1 ELISA Kit; Stimulated T cell chemotactic protein 1 ELISA Kit; Stimulated T-cell chemotactic protein 1 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, cell culture supernates, tissue homogenates
  • 检测范围：
    15.625 pg/mL-1000 pg/mL
  • 灵敏度：
    10.324 pg/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Immunology
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human MDC in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:1 Average % 86  
    Range % 82-95  
    1:2 Average % 92  
    Range % 85-101  
    1:4 Average % 100  
    Range % 94-112  
    1:8 Average % 93  
    Range % 85-98  
  • 回收率：
    The recovery of human MDC spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 85 80-93  
    EDTA plasma (n=4) 89 85-98  
                 
                 
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected  
    1000 2.534 2.421 2.478 2.349  
    500 1.956 1.766 1.861 1.732  
    250 1.147 1.087 1.117 0.988  
    125 0.602 0.611 0.607 0.478  
    62.5 0.341 0.331 0.336 0.207  
    31.25 0.245 0.262 0.254 0.125  
    15.625 0.198 0.201 0.200 0.071  
    0 0.134 0.124 0.129 　  
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 最新研究进展：
        CCL22，全称为C-C motif chemokine ligand 22，是一种细胞因子，属于趋化因子家族。CCL22在体内的生物学功能主要是调节免疫细胞的迁移，特别是对Th2淋巴细胞具有吸引作用，因此被认为在过敏反应、哮喘等炎症性疾病中发挥重要作用。近年来的研究表明，CCL22不仅在炎症反应中起作用，还可能参与肿瘤的发生、发展和预后，成为肿瘤免疫治疗中一个备受关注的靶点。目前，研究人员正在探索针对CCL22的治疗策略以及其在肿瘤免疫疗法中的应用前景。
     
  • 功能：
    May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active.
  • 基因功能参考文献：
    1. MDC might serve as a marker of pharmacological therapy response in major depressive disorder PMID: 28898872
    2. blood CCL22 levels were positively associated with IgE sensitization at age 2. A high cord blood CCL22/CXCL10 chemokine ratio was significantly associated with a higher risk of allergic sensitization at age 3. PMID: 27863395
    3. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 signaling axis. PMID: 28039457
    4. Elevations in serum MDC and BLC were independently associated with the significant risk of early stage lung adenocarcinoma, even in non-smokers and in stage IA patients. PMID: 27811371
    5. CCL22 plays an important role in supporting gastric cancer development presumably by increasing the percentage of regulatory T cells in the tumor microenvironments. CCL22 levels in sera have a predictive value for gastric cancer peritoneal metastasis and the early recurrence. PMID: 28501127
    6. The CCL22-mediated enhancement of antitumor responses is however not due to conversion, but rather to redirection of existing regulatory T cells to the site of cutaneous overexpression. PMID: 27634754
    7. CCL22 and IL-37 with a co-localization in non-small cell lung cancer A549 cells inhibited the proliferation and epithelial-mesenchymal transition process PMID: 27499437
    8. Our results demonstrate that CCL22 is expressed in human placenta. Decidual expression was only observed in miscarriage conditions and correlates with Treg infiltration. PMID: 25922986
    9. Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris. PMID: 26093920
    10. type I IFN blocks the regulatory T cell-attracting chemokine CCL22 and thus helps limit the recruitment of regulatory T cells to tumors PMID: 26432403
    11. First-episode psychosis patients had higher serum CCL22, which decreased substantially following antipsychotic treatment. PMID: 25970596
    12. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression. PMID: 25647263
    13. Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH mutation status. CCL22 should be considered a marker of immune status with potential prognostic value PMID: 25604093
    14. CCL22 is a novel mediator of lung inflammation following hemorrhage and resuscitation PMID: 25136780
    15. CCR4 C1014T and CCL22 C16A genetic variations were neither associated with the risk, nor with the progression of colorectal cancer in Iranian population PMID: 25148803
    16. The serum CCL22 levels were affected by genetic variations at SNP rs223818. Accordingly, SNP rs223818 may play a role in the susceptibility to breast cancer. PMID: 25722218
    17. Sesamin suppressed lipopolysaccharide induced CCL22 expression in monocytes through the ER/PPAR-a, the MAPK-p38 pathway, the NFkB-p65 pathway and the epigenetic regulation by suppressing histone H3/H4 acetylation in the CCL22 promoter region. PMID: 25117529
    18. CCL22 could be an immune marker in ANCA-associated vasculitis. PMID: 25352172
    19. Suggest that lower CCL22 levels may play an important role in the pathogenesis of multiple sclerosis in women. PMID: 24254331
    20. CCL22 is an antimicrobial protein with bacteriocidal activity against E. coli and S. aureus. PMID: 12949249
    21. genetic polymorphism is not associated with breast carcinoma in Southern Iranian population PMID: 23268288
    22. both CCL22 and TGF-beta1 are candidate chemoattractants for intratumoral Foxp3 (+)Tregs infiltration; however, unlike the later, CCL22 is an independent prognostic predictor of BC patients. PMID: 24124553
    23. Autistic children had significantly higher serum levels of MDC than healthy controls PMID: 23782855
    24. Data suggest that decreased levels of plasmatic CCL22 may contribute to CD4(+) lymphopaenia. PMID: 23265706
    25. lymph node metastasis of CCR4(+) HNSCC is promoted by CCL22 in an autocrine or M2-like macrophage-dependent paracrine manner. PMID: 23180648
    26. High cord blood levels of the Th2 related chemokine CCL22 were significantly associated with high total- IgE levels during the first 6 years of life, but not with specific sensitization, asthma, eczema or allergic rhinitis. PMID: 23106659
    27. findings suggest that HBV infection and activity of the TGF-beta-miR-34a-CCL22 axis serve as potent etiological factors to predispose hepatocellular carcinoma patients for the development of portal vein tumor thrombus PMID: 22975373
    28. results suggested that suppression of the CCL22 gene using Salmonella induced anti-inflammatory effects PMID: 21823987
    29. Data suggest that variants of C-C motif chemokine 22 (CCL22) play a role in susceptibility to atopic dermatitis (AD) in a gain-of-function manner. PMID: 22125604
    30. chemokine CCL22 may have a role in abdominal aortic aneurysm PMID: 20348247
    31. CCL22 may be responsible for the infiltration of CD4(+)CD25(high) T cells into the pleural space of patients with tuberculous pleurisy. PMID: 20337996
    32. Plasma concentration of CCL22 correlates with the frequency of circulating CD4-positive FoxP3-positive (CD4+FoxP3+) regulatory T cells (Tregs) in human T-lymphotropic virus (HTLV) type 1-infected subjects. PMID: 20525891
    33. Endocrine disrupting chemicals suppressed CCL22 and IP-10 levels in cultured monocytes via, at least in part, the MKK1/2-ERK MAPK pathway and histone H4 acetylation. PMID: 19756997
    34. Data show that MDC/CCL22 is present in the synovial membrane of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients and in synovial fluid of patients with RA and PsA, which would enable migration of CCR4 expressing memory cells. PMID: 19942450
    35. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22, suggesting a vicious circle, leading to the progressive accumulation of the neoplastic cells. PMID: 11981828
    36. Neither MDC release nor MDC mRNA was detected in any of the 3 types of fibroblasts stimulated with any of the cytokines examined. PMID: 12642832
    37. Serum levels of TARC and MDC in atopic dermatitis patients were significantly higher than those found in normal controls. PMID: 15113590
    38. CCL22 induced accumulation of phosphatidylinositol-(3,4,5)-trisphosphate in the leukemic T cell line CEM. CCL22 also had the ability to chemoattract human Th2 cells and CEM cells in a pertussis toxin-sensitive manner. PMID: 15187160
    39. CCL17 and CCL22, which are constitutively produced by immature DCs, mediate both T cell polarization and attraction. PMID: 15210758
    40. Elevated bronchial mucosal expression of MDC/CCL22 is implicated in asthma pathogenesis; its action is partly through selective development and retention, or recruitment of T helper type 2, not Th1, receptor-bearing cells. PMID: 15944327
    41. MDC/CCL22 has a role in inhibiting progression of lung cancer PMID: 16453150
    42. These data suggest that the CCL22 level produced by monocyte derived dendritic cells thus reflects the disease activity of Atopic dermatitis (AD) and it may also play an important role regarding the production of CCL22 in the pathogenesis of AD. PMID: 17008059
    43. A trend towards a decreased allelic frequency of the A allele of the CCL22 C/A SNP as well as of the T allele of the CCL17 C/T SNP was found in MS patients compared with controls. PMID: 17967467
    44. HTLV-1-infected T cells produce CCL22 through Tax and selectively interact with CCR4+CD4+ T cells, resulting in preferential transmission of HTLV-1 to CCR4+CD4+ T cells. PMID: 18178833
    45. MDC/CCL22 is likely to play a role in the development of multiple sclerosis in females only, possibly influencing the intracerebral recruitment of Th2 cells, which produce anti-inflammatory cytokines PMID: 18208895
    46. Significantly higher CCL22 expression is associated with gastric cancer PMID: 18224687
    47. although IE86 does repress the UL144-mediated activation of a synthetic NFkB promoter, it is unable to block UL144-mediated activation of the CCL22 promoter, and this lack of responsiveness to IE86 appears to be regulated by binding of CREB. PMID: 18287226
    48. serum CCR4 ligands (CCL17 and CCL22)may be useful inflammatory markers for assessing atopic dermatitis severity in children PMID: 18435706
    49. Development of allergic disease is associated with a more marked Th2-like deviation already at birth, shown as increased levels of cord blood IgE and MDC (CCL22) and higher ratios of MDC (CCL22) to IP-10 (CXCL10) and I-TAC (CXCL11). PMID: 19175890
    50. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. PMID: 19244125

    显示更多

    收起更多

  • 亚细胞定位：
    Secreted.
  • 蛋白家族：
    Intercrine beta (chemokine CC) family
  • 组织特异性：
    Highly expressed in macrophage and in monocyte-derived dendritic cells, and thymus. Also found in lymph node, appendix, activated monocytes, resting and activated macrophages. Lower expression in lung and spleen. Very weak expression in small intestine. I
  • 数据库链接：

    HGNC: 10621

    OMIM: 602957

    KEGG: hsa:6367

    STRING: 9606.ENSP00000219235

    UniGene: Hs.534347